AbbVie Inc.(ABBV)Stock Performance & ReturnsNYSE
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
ABBV | 500.94 B | 80.76x | 10.20% | 9.80% | $3.51 | - | - | 2.63% | $269.39 | $190.75 |
950160.KQ | 1.14 T | - | - | - | - | - | - | - | $149000.00 | $11470.00 |
AMGN | 230.37 B | 27.39x | 9.50% | 22.95% | $15.56 | 91.47% | 4.90x | 2.41% | $447.03 | $280.23 |
950220.KQ | 56.53 B | - | 4559.30% | 0.00% | - | -61.03% | 0.20x | - | $4450.00 | $1115.00 |
Peer Valuation & Performance Analysis
Peer group analysis for AbbVie Inc. (ABBV) compared to its primary competitors (including 950160.KQ, AMGN, 950220.KQ) reveals distinct metrics. ABBV trades at a valuation premium compared to its competitors, with a P/E ratio of 80.8x versus the peer average of 27.4x (representing a 195% premium). This indicates that the market expects superior growth or commands a quality premium for ABBV. In terms of growth, ABBV's revenue growth of 10.2% lags behind the peer average of 2284.4%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of 9.8% is comparable to the peer average of 11.5%.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• ABBV ranks #2 in P/E ratio, #2 in revenue growth, and #2 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-14 | $277.00 | $285.40 | $275.97 | $283.48 | 5,624,300 | +3.32% |
| 2026-10-13 | $283.29 | $283.43 | $273.70 | $274.36 | 6,408,500 | -2.40% |
| 2026-10-12 | $277.65 | $281.30 | $276.01 | $281.12 | 5,593,700 | +1.68% |
| 2026-10-09 | $271.53 | $277.60 | $270.38 | $276.47 | 4,297,400 | +1.49% |
| 2026-10-08 | $270.98 | $272.52 | $265.71 | $272.42 | 5,492,300 | +0.39% |
| 2026-10-07 | $268.40 | $274.94 | $266.89 | $271.36 | 6,077,000 | +1.75% |
| 2026-10-06 | $267.74 | $268.86 | $260.62 | $266.69 | 4,500,700 | +0.35% |
| 2026-10-05 | $261.27 | $267.34 | $260.29 | $265.76 | 7,542,000 | +1.12% |
| 2026-10-02 | $259.74 | $264.06 | $257.87 | $262.82 | 5,861,400 | +1.11% |
| 2026-10-01 | $260.51 | $262.32 | $259.00 | $259.93 | 3,889,900 | -0.63% |
| 2026-09-30 | $264.60 | $265.36 | $261.59 | $261.59 | 4,386,600 | -0.65% |
| 2026-09-29 | $265.45 | $268.93 | $261.52 | $263.29 | 4,004,200 | -1.12% |
| 2026-09-28 | $264.33 | $267.74 | $263.38 | $266.28 | 4,421,300 | +0.73% |
| 2026-09-25 | $265.49 | $266.00 | $262.59 | $264.34 | 2,540,400 | -0.29% |
| 2026-09-24 | $265.37 | $267.41 | $263.09 | $265.12 | 3,456,000 | +0.02% |
Explore More Analysis for ABBV
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.